L-(+)-methylenetetrahydrofolic acid clinical trials
Also written Arfolitixorin and ISO-901.
How each study uses L-(+)-methylenetetrahydrofolic acid is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the L-(+)-methylenetetrahydrofolic acid studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Isofol Medical AB (5) · Vastra Gotaland Region (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses L-(+)-methylenetetrahydrofolic acid is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Clinical Study of Arfolitixorin in Patients With mCRCRecruitingPhase 1/2Isofol Medical ABNCT06922383Written as Arfolitixorin
- A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal CancerCompletedPhase 3Isofol Medical ABNCT03750786Written as Arfolitixorin
- PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon CancerCompletedPhase 1/2Isofol Medical ABNCT01681472Written as 6R-MTHF (arfolitixorin) 200 mg/m2
- Study Evaluating ECG Effects, Safety, Tolerability and Pharmacokinetics of Single Doses of Modufolin (Arfolitixorin) in Healthy Volunteers Tetrahydrofolate in Healthy Male VolunteersCompletedPhase 1Isofol Medical ABNCT03203564Written as Modufolin (arfolitixorin)
- Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal CancerCompletedPhase 1/2Isofol Medical ABNCT02244632Written as Modufolin (arfolitixorin)
- Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and CalciumfolinateStatus unknownPhase 1/2Vastra Gotaland RegionNCT04126655Written as Arfolitixorin
Codes
What other systems call L-(+)-methylenetetrahydrofolic acid · ClinicalTrials.gg INT018673
- UNII (FDA) Z8R4A37V9QARFOLITIXORINConfirmed FDA, Wikidata
- Wikidata Q26995704L-(+)-methylenetetrahydrofolic acidConfirmed FDA, Wikidata
- DrugBank DB12676One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z8R4A37V9Q | ARFOLITIXORIN | Confirmed FDA, Wikidata |
| Wikidata | Q26995704 | L-(+)-methylenetetrahydrofolic acid | Confirmed FDA, Wikidata |
| DrugBank | DB12676 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.